Table 7.

Passive immunotherapy for SARS-CoV-2 in clinical trials.

Phase	Responsible party	Interventions	Recruitment status	Population (enrollment and age)	NCT number
Early 1	Tongji Hospital	● Recombinant human interferon α1β	Not yet recruiting	328 ≤18	NCT04293887
2	First Affiliated Hospital of Wenzhou Medical University	● Thalidomide	Not yet recruiting	100 ≤18	NCT04273529
Not applicable	Tongji Hospital	● Tocilizumab ● Standard of care Procedure: continuous renal replacement therapy	Recruiting	120 18–80	NCT04306705
2	First Affiliated Hospital of Fujian Medical University	● Fingolimod	Recruiting	30 ≤18	NCT04280588
2, 3	Fasa University of Medical Sciences	● Levamisole pill with budesonide with formoterol inhaler ● Lopinavir with ritonavir with hydroxychloroquine	Not yet recruiting	30 18–100	NCT04331470
2	First Affiliated Hospital of Wenzhou Medical University	● Thalidomide	Not yet recruiting	40 ≤18	NCT04273581
2, 3	Qilu Hospital of Shandong University	● Bevacizumab injection	Recruiting	20 ≤18	NCT04275414
2, 3	Peking Union Medical College Hospital	● Methylprednisolone therapy ● Standard care	Recruiting	80 ≤18	NCT04244591
3	Tongji Hospital	● Sildenafil citrate tablets	Recruiting	10 ≤18	NCT04304313
4	Tongji Hospital	● Methylprednisolone	Recruiting	100 ≤18	NCT04263402
Not applicable	Beijing Chao Yang Hospital	● Methylprednisolone	Recruiting	400 ≤18	NCT04273321
–	Hudson Medical	● Eculizumab	Available	– ≤18	NCT04288713
4	University Hospital, Ghent	● Usual care ● Anakinra ● Siltuximab ● Tocilizumab	Not yet recruiting	342 18–80	NCT04330638
2	Southeast University, China	● PD-1 blocking antibody with standard treatment ● Thymosin with standard treatment ● Standard treatment	Not yet recruiting	120 ≤18	NCT04268537
Not applicable	University of Palermo	Dietary supplement: vitamin C	Recruiting	500 All	NCT04323514
Not applicable	Peking Union Medical College Hospital	● Intravenous immunoglobulin ● Standard care	Not yet recruiting	80 ≤18	NCT04261426
2	Assistance Publique - Hôpitaux de Paris	● Tocilizumab	Not yet recruiting	240 ≤18	NCT04331808
Not applicable	Shanghai Public Health Clinical Center	● Inactivated convalescent plasma	Recruiting	15 All	NCT04292340
2	Xijing Hospital	● Nitric oxide gas	Not yet recruiting	104 ≤18	NCT04290871
2	Massachusetts General Hospital	● Nitric oxide	Not yet recruiting	240 ≤18	NCT04305457
Not applicable	Foundation IRCCS San Matteo Hospital	● Hyperimmune plasma	Active, not recruiting	49 ≤18	NCT04321421
2	Southeast University, China	● PD-1 blocking antibody with standard treatment ● Thymosin with standard treatment ● Standard treatment	Not yet recruiting	120 ≤18	NCT04268537
2, 3	Regeneron Pharmaceuticals	● Sarilumab	Recruiting	400 ≤18	NCT04315298
4	Negrin University Hospital	● Dexamethasone	Not yet recruiting	200 18	NCT04325061
2	Università Politecnica delle Marche	● Tofacitinib	Not yet recruiting	50 18–65	NCT04332042
3	Assistance Publique - Hôpitaux de Paris	● Discontinuation of RAS blocker therapy ● Continuation of RAS blocker therapy	Not yet recruiting	554 ≤18	NCT04329195
3	OncoImmune, Inc.	● CD24Fc	Not yet recruiting	230 ≤18	NCT04317040
Not applicable	University Health Network, Toronto	● Ruxolitinib	Not yet recruiting	64 ≤12	NCT04331665
2	National and Kapodistrian University of Athens	● Colchicine ● Standard treatment	Not yet recruiting	180 ≤18	NCT04326790
3	Assistance Publique - Hôpitaux de Paris	● Usual practice with SYMBICORT RAPIHALER ● Usual practice	Not yet recruiting	436 18–75	NCT04331054
Not applicable	Wuhan Union Hospital	● Immunoglobulin of cured patients ● γ-Globulin	Not yet recruiting	10 ≤18	NCT04264858
3	Shanghai Jiao Tong University School of Medicine	● Recombinant human interferon alpha-1b ● Thymosin alpha 1	Recruiting	2944 18–65	NCT04320238
3	Misr University for Science and Technology	●Dietary supplement: natural honey ● Standard care	Not yet recruiting	1000 5–75	NCT04323345
1, 2	Chinese Academy of Sciences	● CAStem	Recruiting	9 18–70	NCT04331613
2	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	● Anti-SARS-CoV-2 plasma ● SARS-CoV-2 non-immune plasma	Not yet recruiting	150 ≤18	NCT04323800
2	Universidad del Rosario	● Plasma	Not yet recruiting	10 18–60	NCT04332380
3	Assistance Publique - Hôpitaux de Paris	● Naproxen ● Standard of care	Not yet recruiting	584 ≤18	NCT04325633
2, 3	Universidad del Rosario	● Plasma ● Hydroxychloroquine ● Azithromycin	Not yet recruiting	80 18–60	NCT04332835
3	Estudios Clínicos Latino América	● Colchicine ● Local standard of care	Not yet recruiting	2500 ≤18	NCT04328480
Not applicable	Mazandaran University of Medical Sciences	● Convalescent plasma	Enrolling by invitation	30 30–70	NCT04327349
2	Zhongnan Hospital	● Vitamin C ● Sterile water for injection	Recruiting	140 ≤18	NCT04264533
3	Hospital Sirio-Libanes	● Dexamethasone	Not yet recruiting	290 ≤18	NCT04327401
3	Hospital of Prato	● Baricitinib	Recruiting	60 18–80	NCT04320277
Not applicable	Jiangxi Qingfeng Pharmaceutical Co. Ltd.	● Xiyanping injection ● Lopinavir with ritonavir, alpha-interferon nebulization	Not yet recruiting	348 18–70	NCT04275388
2, 3	University of Trieste	● Methylprednisolone ● Standard care	Recruiting	104 18–80	NCT04323592
2	Mayo Clinic	● Convalescent plasma	Not yet recruiting	20 ≤18	NCT04325672
2	Upinder Singh, Stanford University	● Peginterferon lambda-1a ● Standard of care treatment	Not yet recruiting	120 18–64	NCT04331899
3	Montreal Heart Institute	● Colchicine	Recruiting	6000 ≤40	NCT04322682
2	Lucio Manenti, Azienda Ospedaliero-Universitaria di Parma	● Colchicine	Not yet recruiting	100 18–85	NCT04322565
2	National Cancer Institute, Naples	● Tocilizumab injection	Recruiting	330 All	NCT04317092
3	Hoffmann-La Roche	● Tocilizumab (TCZ)	Not yet recruiting	330 ≤18	NCT04320615
2	Università Politecnica delle Marche	● Tocilizumab	Not yet recruiting	30 18–90	NCT04315480
1	Hospital San Jose Tec de Monterrey	● Convalescent plasma	Not yet recruiting	20 ≤18	NCT04333355
2	Massachusetts General Hospital	● Nitric oxide gas	Recruiting	220 18–99	NCT04306393
Not applicable	Beijing 302 Hospital	● Conventional medicines and traditional Chinese medicines granules ● Conventional medicines and lopinavir with ritonavir	Not Applicable	150 14–80	NCT04251871
2	Frederiksberg University Hospital	● RoActemra iv ● RoActemra sc ● Kevzara sc ● Standard medical care	Not yet recruiting	200 ≤18	NCT04322773
2, 3	Assistance Publique - Hôpitaux de Paris	● Sarilumab	Recruiting	240 ≤18	NCT04324073
2	University of British Columbia	● Nitric oxide 0.5% with nitrogen 99.5% gas for inhalation	Active, not recruiting	20 ≤14	NCT03331445
3	Université de Sherbrooke	● Vitamin C ● Control	Recruiting	800 ≤18	NCT03680274
2, 3	Swedish Orphan Biovitrum	● Emapalumab ● Anakinra	Not yet recruiting	54 30–79	NCT04324021